DaVita Inc. (NYSE:DVA) Shares Purchased by Ethic Inc.

Ethic Inc. lifted its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 116.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,345 shares of the company's stock after buying an additional 2,340 shares during the period. Ethic Inc.'s holdings in DaVita were worth $650,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. SBI Securities Co. Ltd. acquired a new position in shares of DaVita during the 4th quarter worth $41,000. Coppell Advisory Solutions LLC raised its holdings in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after purchasing an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in DaVita during the fourth quarter worth $55,000. Venturi Wealth Management LLC increased its position in shares of DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after buying an additional 152 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after buying an additional 131 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Trading Up 1.7%

DVA stock traded up $2.48 during trading on Tuesday, reaching $147.44. 146,003 shares of the stock traded hands, compared to its average volume of 828,244. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 52-week low of $131.44 and a 52-week high of $179.60. The firm has a market capitalization of $11.13 billion, a PE ratio of 13.70, a P/E/G ratio of 1.07 and a beta of 1.14. The business's 50 day moving average price is $145.72 and its 200-day moving average price is $153.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The company had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.26 earnings per share. As a group, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on DVA shares. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Truist Financial dropped their price objective on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.